trending Market Intelligence /marketintelligence/en/news-insights/trending/MnSVC9xy10c53RhKudCOGg2 content esgSubNav
In This List

AstraZeneca's Viela Bio partners with Mitsubishi Tanabe for drug development

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AstraZeneca's Viela Bio partners with Mitsubishi Tanabe for drug development

AstraZeneca PLC's spinout Viela Bio Inc. entered a collaboration with Mitsubishi Tanabe Pharma Corp. to develop and commercialize its lead product candidate inebilizumab in nine Asian regions.

Viela's inebilizumab was granted orphan drug designation by the U.S. Food and Drug Administration in 2016 and by the European Medicines Agency in 2017 for treating neuromyelitis optica spectrum disorder, a disease in which the immune system attacks a patient's eye nerves and spinal cord.

The U.S. Food and Drug Administration recently accepted Viela's biologics license application regarding inebilizumab for the same indication for review.

As part of the collaboration deal, Viela will get an up-front licensing fee of $30 million in addition to payments tied to certain development and commercial milestones as well as sales revenue.

Japanese pharmaceutical company Mitsubishi, under the collaboration, will target Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, Philippines, Singapore and Taiwan, Gaithersburg, Md.-based Viela Bio said in an Oct. 9 press release.